A B S T R A C T We have developed a radioimmunoassay for human thrombin using rabbit anti-human thrombin IgG. The assay can measure 2 ng thrombin/ml plasma, 500-fold more sensitive than clotting assays. Human prothrombin is less reactive in the assay than thrombin by at least four orders of magnitude, and there is no demonstrable cross-reactivity with human factor Xa, the clotting factor structurally most similar to thrombin. The assay does not detect thrombin bound to antithrombin III. Using the assay, we have demonstrated that plasma from 20 normal subjects does not contain detectable thrombin.
INTRODUCTION
Studies designed to clarify the processes involved in blood coagulation have been limited in the past by the available technology for measuring the individual Received for publication 23 April 1976 and in revised form 19 July 1976. components. The classical approach has been to assay the involved enzymatic factors on the basis of their functional activity. In most cases this involved using plasma deficient in the enzyme or factor to be assayed, or plasma from which the particular factor has been removed. This approach has been limited by the availability of factor-deficient plasma and by the difficulty of preparing plasma selectively and totally deficient in individual factors. Furthermore, these assays are usually indirect in that the end-point is based on the clotting of fibrinogen, which in turn is dependent on several other factors.
The standardized fibrinogen clotting assay is accurate at concentrations of thrombin greater than 1 ,tg/ml (3 U/ml) (1) . A number of clotting factors other than fibrinogen, including factors V and VIII and platelets, are affected by thrombin concentrations lower than 1 Ag/ml when studied in vitro (2) (3) (4) .
It is possible that low levels of thrombin generated early in hemostasis are important to the overall process. The clotting assay has limited usefulness to study these processes in whole blood because at the level of thrombin detectability clotting takes place and serum is formed.
to start the reaction with an activated zymogen, i.e., factor Xa, is arbitrary and concedes the initial activating steps. Third, the actual quantitative relationships of the various activated factors in clotting blood are unknown, and thus reactions carried out in buffered systems are arbitrary in regard to the concentration of factors used.
The present study was designed to provide a technique whereby the kinetics of thrombin formation can be investigated under more physiologic conditions in the presence of other activities and with greater sensitivity. We describe a radioimmunoassay for measuring human thrombin in nanogram quantities. Thrombin levels in blood can be determined and appear to reflect active thrombin. Using the assay we have measured the generation of thrombin in clotting blood.
METHODS
Human thrombin used in these experiments was either purified as previously described (4, 13) Dr. Milan Wickerhauser, National Fractionation Center, American Red Cross, Bethesda, Md.) was the starting material rather than plasma. The human prothrombin when fully activated had a specific activity of 1,400 NIH thrombin U/mg prothrombin. Bovine thrombin was purified from topical thrombin (Parke, Davis & Co., Detroit, Mich.) by the method of Glover and Shaw (14) . It had a specific activity of 2,200 NIH U/mg. Bovine prothrombin was kindly provided by Dr. C. M. Jackson (8) . It had a specific activity of 1,240 NIH thrombin U/mg prothrombin when fully activated.
Human factor X was a gift from Dr. Robert Rosenberg (11) . Activation was accomplished by incubating factor X in 0.15 M NaCl, 0.02 M Tris-HCl, pH 7.7, 0.01 M CaCl2 containing 50 ,ul/ml of a stock suspension of rabbit brain cephalin (Sigma Chemical Co., St. Louis, Mo.), and 0.1 mg/ml of the venom from Vipera Russellii (snake venom, Sigma) for 30 min at 20°C. Factor Xa activity was assayed as previously described (15) , with plasma deficient in factors VII and X (Sigma).
Preparation of human antithrombin III. Antithrombin III was purified by a modification of the method described by Yin et al. (16) . To 500 ml of fresh human plasma adsorbed twice with 100 mg/ml barium sulfate, 200 ml of buffer (0.15 M NaCl, 0.02 M Tris-HCl, pH 7.4, 0.02% sodium azide) was added. The pH was adjusted to 7.2 with 0.1 N HCl, 50 ml of 4% 6,9-diamino-2-ethoxyacridine lactate (Rivanol, Sigma) in ethanol was added, and the mixture was stirred for 13h at 4°C. The precipitate was removed by centrifugation at 10,400 g for 20 min. The supernatant was dialyzed against buffer (0.15 M NaCl, 0.02 M Tris-HCl, pH 7.4, 0.02% sodium azide) with several changes for 5 (18) . Assay of antithrombin III activity. An appropriate dilution of the sample to be assayed was incubated at 370C in 0.5 ml of 0.14 M NaCl and 0.01 M Tris-HCl, pH 7.4 containing 2 U of heparin and 2.5 U of thrombin. After 10 min, 0.1 ml was removed and added to 0.3 ml of the standard thrombin assay mixture and 0. Preparation of antibody. The rationale and method of immunization of rabbits with human DIP-thrombin have been described (4) . After primary immunization with 1.0 mg of human thrombin, booster immunizations were carnred out at 4-6-wk intervals with 0.2 mg of thrombin. The titer of the antisera was assessed by measuring the degree of inhibition of the conversion of fibrinogen to fibrin by thrombin. The antithrombin antibody used in these experiments described below (HAT-35) was obtained approximately 5 mo after initial immunization; 250 U of thrombin were neutralized by 1 ml of HAT-35 antiserum (4).
The IgG fraction of antisera was prepared by DEAE cellulose (DE23, Whatman Chemicals, Div. W. & R. Balston, Kent, England) chromatography (20) .
Radioimmuntoassay. The reactions were carried out at 0°C in a total volume of 0.2 ml in 1.5 ml Eppendorf micro test tubes (Brinkmann Instruments, Inc., Westbury, N. Y.), previously soaked in 0.5% albumin.
The incubation buffer and the buffer in which all dilutions were made was 0.15 M NaCl, 0.01 M Tris-HCl, pH 7.4, and contained 0.5% albumin and 0.01 M benzamidine (Aldrich Chemical Co., Inc., Milwaukee, Wis., the latter to inhibit proteolysis). The reaction mixture contained the following: test sample, 5 gl (0.05-0.1 ,ug of protein) of anti-human thrombin IgG (an amount that gives 40-60% precipitation of 1251-DIP-thrombin tracer; with excess antibody, 82% of tracer is precipitable) and 2 ,ul (5 ,ug of protein) of non-immune rabbit IgG. After incubation for 2 h, 5 ,l of 125I-DIP thrombin (104 cpm/0.1 ng) was added, and the incubation was continued for an additional 16 h. Preincubation of test samples with antithrombin IgG for 2 h before addition of the labeled antigen resulted in a twofold increase in sensitivity of the assay; longer preincubation did not further increase the sensitivity. The IgG fraction of goat anti-rabbit IgG antisera (antisera obtained from Gateway Immunosera Co., Cahokia, Ill.), 0.2 mg in 15 ,ul was then added to each reaction mixture. Incubation was continued for an additional 6 h. After addition of 0.8 ml of buffer, the immunoprecipitates were collected by centrifugation at 14,000 g for 15 min. The supernatant solutions were removed, and the test tubes containiing the precipitated 125I-DIP-thrombin were counted in a Packard gamma scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.). Each reaction was performed in duplicate. The amount of tracer specifically bound to antithrombin IgG was determined after subtracting the amount of radioactivity precipitated in incubations where only nonimmune IgG was present. The radioactivity precipitated in these samples resulted in correction of less than 2.5% of the total amount of tracer precipitable by immune IgG.
In experiments where plasma was assayed, the volume of the reaction mixture was also 0.2 ml, of wvhich 0.1 ml was plasma. Thus, 1-100 Al of test plasma was added to sufficient control plasma (see below) to provide a total of 0.100 ml. In the standard displacement curve with unlabeled thrombin, control plasma was used. The assay was otherwise identical to that described above. For all assays, IgG fractions of antisera were used to avoid the problems created by the antisera-contained activated clotting factors.
Preparationi of cotntrol plasmt a. Freshly drawn blood was anticoagulated with either acid citrate dextrose (ACD)3 or sodium heparin (Riker Laboratories, Northridge, Calif.) in a final concentration of 5 U/ml. iPr2PF was added to a final concentration of 0.01 M1 with 1 M iPr2PF in isopropanol, and the blood was kept at O°C for 15 min.
Theni 0.5 NI benizamidinie was addedl to a fincal coieeintrationi of 0.01 M, and the blood was centrifuged at 12,000g for 15 min. The plasma was then passed over an Amberlite CG-50 polymethylacrylic acid resin column (200-400 mesh particle size, Mallinckrodt Inc.) equilibrated in 0.15 NI NaCl (bed volume equal to twice the plasma volume). This column removed traces of thrombin efficiently since when '251-DIP-thrombin in concentrations of 0.2-200 ng/ml was added to the plasma, more than 90% of the thrombin bound to the resin, based on the radioactivity remaining in the effluent plasma. Whether the latter actually reflected thrombin or Nwas free iodide or other material was not investigated further.
3 ACD was used in 1:7 (vol/vol) ratio in all experiments.
Radioimnutnoassay of throninbbin int ntormal subjects. Blood was drawn from 10 male and 10 female healthy subjects between the ages of 20 and 50 with 19-gauge needles. The first 5 ml of blood collected was discarded. ACD was added as the anticoagulant to 10 ml of blood, and samples were adjusted to contain 0.01 MI benzamidine with 0.5 M benzamidine. Plasma obtained after centrifugation at 12,000 g for 15 min was assayed as described above.
Radioimmunzoassay of throinbin in clotting blood. Blood was drawn through a 15-gauge needle (AE-6 plasma transfer set; Fenwal Inc., Walter Kidde & Co., Inc., Ashland, NMass.). "Zero" time was considered to be when blood was initially seen entering the tubing attached to the needle. The first 10 ml was discarded, and 30 ml of blood was collected into a polypropylene tube and placed either on ice or at 22°C. Portions of 1 ml were taken from the pool at 1-mim intervals and added to tubes containing ACD or heparin (60 U/ml), and 1.0 NI iP,2 PF in isopropanol wvas added immediately (final concentration 0.01 NI). Samples were kept oIn ice for 20 min, and 0.5 NI benzamidine was then added to a final concentration of 0.01 NI. Blood samples were centrifuged at 1,800 g for 10 min, and the plasma was removed and immediately assayed for thrombin content.
Measurement of thromibbi genierationi by radioimnmzutnoassay after in vitro activatiotn of prothromibitn by factor Xa, Ca2', and phospholipid. Humani prothromiibiin, 20 ug/ml, was incubated at 37°C in buffer (0.15 NI NaCl, 0.02 M Tris-HCl, pH 7.4, 2 mNI CaCl2) containing 25 Al/mIil of a stock suspension of rabbit brain cephalin. Bovine factor X02, 0.5 U/ml was added, aliquots were removed at intervals, and further activation wvas inhibited by the addition of 0.05 NI EDTA and 1.0 iPr2PF at final concentrations of 2 mM and 0.01 NI, respectively. Samples were kept at 00 for 15 min, and then 0.5 NI benzamidine was added to a final concentration of 0.01 NI.
Immunoassay of thrombin-antithrotnbin III complex.
Thrombin or DIP-thrombin, 1 ,ug in 25 gl, and 20.0 ,ug of 1311-antithrombin III in 0.07 ml (5 x 105 cpm/4ug) were added to heparin (20 U) in 0.905 ml of 0.15 M NaCl, 0.01 M Tris-HCl, pH 7.4, 0.5% albumin. A third reaction mixture was similar except that it contained neither native or DIP-thrombin. After 10 min at 37°C, aliquots were removed from each reaction mixture, and thrombin concentration was determined by radioimmunoassay.
Determinhation of the thromiibitn conztent of the humiani f(actor Xa preparatio iby clotting assay. Factor X was activated with Russell's viper venom as described above. A standard curve was constructed based oIn results of the fibrinogen clotting assay with small amounts of thrombin (0.01-5 U/ml) and used as a reference to estimate the thrombin content of the mixture containing factor X0.
Effect of anitithromizbint IgG oni the fibrinogeni clottin,g activity of the Xa preparation. 5 The amount of thrombiin present in each instance was determined based on the clotting time in comparison to a standard curve with thrombin.
The thrombin clotting assay was performed as described (20) , with human fibrinogen prepared from fresh frozen plasma in one-half the standard volume to increase sensitivity (21) .
RESULTS
Thrombitn radioiinmmunoa,ssai. The radioimmunoassay of pure huLmain thrombin was Fig. 3 , there is an apparent 2,000-fold difference in reactivity between thrombin and factor X,L. However, the slopes ofthe displacement curves are virtually identical-0.3. This suggests that the displacement seen with factor Xa results from contamination of the factor X with traces of prothrombin, converted to thrombin by factor Xa after activation. The contamination of factor X with 0.05% prothrombin could not be detected by SDS-polyacrylamide gel electrophoresis (the factor X gave a single band on electrophoresis). To confirm that the displacement seen by the factor Xa preparation was due to thrombin and not true cross-reactivity, a clotting assay for thrombin was carried out with fibrinogen. To avoid the problem of slight displacement of 1251-DIP thrombin in assays with varying plasma content, all assays were performed in the presence of a constant amount of plasma (0.1 ml) in the total 0.2 ml reaction. Any cross-reactivity with prothrombin is "absorbed out" in each reaction mixture. As shown in Fig. 4 , the assay was as sensitive when carried out in a reaction mixture containing 0.1 ml plasma as in buffer (compare to Fig. 1 ). The amount of HAT-35 IgG used in the plasma assay was 1.5-to 3-fold greater than that needed in the buffer assay to achieve an equivalent 50% precipitation of 1251-DIP thrombin. This is probably explained by either cross-reacting prothrombin and/or an effect of some other unidentified plasma component.
When either 0.010 or 0.1 ml of plasma from each of 20 healthy volunteers was assayed, there was no detectable displacement of tracer 1251-DIP thrombin compared with the control, "thrombin-free" plasma (Fig. 4) . This indicates that thrombin is not normally present in human blood (within the limits of detectability of our system-less than 2.0 ng of thrombin/ml plasma), and suggests that no thrombin is generated during the radioimmunoassay procedure itself.
We have also measured plasma thrombin levels in a small series of 14 consecutive hospitalized patients who have had normal prothrombin times, and partial thromboplastin times as determined in the Barnes Hospital Hemostasis Laboratory (St. Louis, Mo.). These patients had slightly elevated plasma thrombin levels compared to laboratory personnel, 2.4±+0.3 ng (SD) thrombin/ml plasmia. Most of the patients had coagulation tests ordered as a routine preoperative workup. The highest thrombin level in this series was 3.2 ng thrombin/ml plasma in a patient 1 day after common bile duct exploration and FIGURE 4 Standard curve of the radioimmunoassay of thrombin in plasma and assay of normal subjects. Plasma from 10 normal males was assayed at two levels: 10 drawn, clotting blood. The results of two experiments representative of eight such experiments are shown in Fig. 5A and B. The lag from the time of venipuncture until the first appearance of thrombin ranged up to 6 min. Initially, a small quantity of thrombin, 2-3 ng (6-9 mU/ml plasma) was seen. Subsequently, there was a variable lag in the further generation of additional thrombin, followed by a progressive but nonlinear generation of thrombin until at levels of 45-55 ng thrombin/ml (0.15 U/ml) of plasma, clotting occurred. There was continued generation of thrombin after clotting with a maximum increase in thrombin levels about 30 min later (300-500 ng/ml plasma, data not shown). Finally approximately 1% of the prothrombin present in blood is converted to thrombin. In two of the eight experiments, thrombin appeared in the first sample after venipuncture, rather than after the lag described above.
Assay of antithrombin II-thrombin complex. Next, we determined whether the thrombin being measured in the immunoassay was bound to antithrombin III. Since it has been demonstrated that thrombin (but not DIP-thrombin) is bound to antithrombin III and formation of this complex is greatly facilitated by heparin (24), we performed experiments in which known amounts of native and DIPthrombin were added to plasma anticoagulated with (34) . The assay described here is highly sensitive and specific for human thrombin. As little as 2 ng/ml can be detected. Furthermore, plasma samples can be readily assayed without prior preparative procedures within approximately 24 h.
The antithrombin antibody is specific for human thrombin as evidenced by the very limited crossreactivity with bovine thrombin. There was no crossreactivity with human factor Xa; there is approximately 10,000-fold less reactivity with human prothrombin than with human thrombin, and thus the zymogen does not significantly interfere with the thrombin assay in plasma. It appears that the prothrombin activation intermediates do not cross-react significantly when thrombin is assayed in plasma. This does not indicate that the antibody does not recognize determinants on these molecules, only that in the presence of a large concentration of prothrombin small amounts of the intermediates do not displace the tracer thrombin. If pure intermediates were assayed in buffer, they might react with the antibody, as bovine prothrombin and intermediates react with antibodies to prothrombin and intermediates (35) . Considering the marked antigenic difference between thrombin and prothrombin, one would not expect significant cross-reactivity between thrombin and any zymogens of the other serine proteases involved in coagulation, although considerable amino acid sequence hematology has been demonstrated in the amino-terminal portions of bovine factors II, IX, and the light chain of X (26) . It is possible that there is cross-reactivity between a-, ,B-, and y-thrombin, the latter two being degradative products of the active molecule with considerably less clotting activity than a-thrombin. If this is the case, the results of the experiments in which thrombin levels were measured in clotting blood would be no less meaningful, since the appearance of /3 and 'y-thrombin is presumably preceded by the active molecule, a-thrombin.
It was important to establish that the small amount of what appears to be thrombin generated in the first few minutes after venipuncture was actually thrombin. The inability to detect this immunoreactive material in the presence of heparin suggests that it is thrombin rather than prothrombin intermediates, since the latter do not bind to antithrombin III. Additionally, when prothrombin was incubated with thrombin, converting it to prethrombin 1 than the thrombin added initially (data not shown). This suggests that there was little cross-reactivity between prethrombin 1 and thrombin. The significance of the presence of thrombin early in the clotting process is not known. It is known, however, that thrombin added in low concentrations will activate platelets (0.01-0.1 U/ml) suspended in buffer (4) or factor V (0.1-0.8 U/ml) also in a buffered system (2) . Factor VIII is converted to the "active" form when small amounts of thrombin (0.03-0.1 U/ml) are added to plasma (3) . It may be that even smaller amounts of endogenously generated thrombin activate these factors in whole blood. Our experiments detected between 2 and 3 ng of thrombin/ml (8 mU/ml) plasma long before clotting occurred, an amount undetectable in previous studies of prothrombin activation. Thus, it may be that small amounts of thrombin are important in initiating clotting by activating the above factors. Further experiments are necessary to determine the precise details of the kinetics of thrombin formation. Further, we do not know whether the thrombin we measured in clotting blood represents the total amount found or whether only free thrombin is measured and that bound to the platelet receptor, clotting factors, or inhibitors is not measured.
Nossel and co-workers have indirect evidence that thrombin is present in minute amounts at the beginning of blood clotting (36) . Using a radioimmunoassay for fibrinopeptides (37) , formed when thrombin cleaves fibrinogen, they found increasing amounts of fibrinopeptides present from the very beginning of blood collection, indicating the presence of biologically active thrombin.
The origin of thrombin so early in the clotting process is unknown. Whether very small amounts of tissue factor released at the time of venipuncture are able to activate the extrinsic clotting pathway, resulting in thrombin formation, remains to be determined. The thrombin we are measuring in plasma is not bound to antithrombin III, as demonstrated by the experiments in which native thrombin is poorly detected by radioimmunoassay in heparinized plasma, nor by the direct assay of the thrombin-antithrombin III complex. Our experiments suggest the feasibility of studying the kinetics of activation of other factors, i.e., XI, IX, X, and their interrelationship with prothrombin activation by use of radioimmunoassay for these factors.
